Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: GlaxoSmithKline PLC
Current Parent Company: GSK plc
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Recap of Ownership Changes:  subscribe to see this data field
Penalty: $92,000,000
Year: 2004
Date: July 8, 2004
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: GlaxoSmithKline agreed to pay $92 million to settle lawsuits alleging it gamed patents to delay the introduction of a generic alternative to its antibiotic Augmentin. The move was announced in a company press release: (click here)
Level of Government: federal
Action Type: private litigation
Court: Eastern District of Virginia
Civil or Criminal Case: civil
Case ID: 2:02cv442
Case Name: Ryan-House, et al v. GlaxoSmithKline Plc, et al
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: United Kingdom
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.